# CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct05942300/  
OnCo record `nct05942300` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of tulmimetostat (CPI-0209) with carboplatin in platinum-sensitive recurrent ovarian cancer, run by Lan Coffman, now recruiting.

## Summary

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer is a phase 1 interventional study registered as NCT05942300 by Lan Coffman, with Novartis Pharmaceuticals, National Cancer Institute (NCI) as collaborators; 30 participants are planned, it started on 2024-01-30; the registry gives 2028-07-31 as its primary completion date. Interventions recorded: CPI-0209, carboplatin. Conditions listed: Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05942300
- Phase: 1
- Setting: Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
- Sponsor: Lan Coffman
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05942300: https://clinicaltrials.gov/study/NCT05942300

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Tulmimetostat](https://onco.cc/drugs/tulmimetostat/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct05942300.json